anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The historical standard for treatment of chronic subdural hematomas (SDH) has been through surgical evacuation through burr holes or craniotomies. Many of these patients are elderly patients who are high risk surgical candidates. Unfortunately given the pathophysiology of SDHs there is a high rate of recurrence ranging 5-30% in the literature necessitation frequent imaging, increased length of hospital stay, increased morbidity, and increased rate of reoperations. A more novel and less invasive approach has been used to treat SDHs in this patient population. There are increasing reports of endovascular embolization of the middle meningeal artery using a less invasive endovascular approach for SDHs. The reported outcomes in literature have been very positive when endovascular embolization has been used without surgery or as an adjuvant to surgery. These reports include case series and retrospective reviews. There have been no studies directly comparing endovascular embolization following surgical evacuation to assess if this technique can actually benefit patients with chronic SDHs. The investigators propose to study this treatment process by randomly assigning patients who have undergone surgical evacuation of SDHs through burr holes into a control and treatment group. The control group (surgery) would only receive surgical evacuation of the hematoma using current standard of care. The treatment group (surgery plus) would receive surgical evacuation followed by endovascular embolization of the middle meningeal vessels using current standard of care. We will directly compare these two treatment modalities to obtain class I evidence on the efficacy of embolization for treatment of chronic subdural hematomas.
Systems and methods for determining infectious disease states are provided. An ensemble classifier is obtained using a training dataset including labels and attribute values for a plurality of genes including at least 20 genes selected from one or more of Table 1, Table 2, Table 8, and Table 9. For each of a plurality of random seeds, initial classifiers with pseudo-randomly assigned hyperparameters are binned and downsampled using evaluation scores obtained from one or more iterations of K-fold cross-validation. The ensemble classifier is formed from initial classifiers with the best score for each random seed. Infectious disease states are determined for a test subject by inputting attribute values for the plurality of genes to a trained ensemble classifier. Compositions and kits for determining infectious disease states, including amplification primers for the plurality of genes, are further provided.
Rheumatoid Arthritis (RA) is a chronic, progressive autoimmune disease, involves an intimate relationship between immune cells and cytokines and results in decreased lifespans and higher mortality rates. The goal of the current study was to investigate the impact of MicroRNA (miRNA)146a and interleukin-17 (IL-17) as prognosis markers in RA patients. This case-control study included 120 RA patients who visited the Rheumatology unit at Al-Saddar Medical City in the governorate of Najaf, and 30 normal controls. Venous blood samples were collected from both patients and controls. Blood samples were used for measuring IL-17 levels using an enzyme linked immunosorbent assay (ELISA) testing, and miRNA146a by the reverse transcription polymerase chain reaction (RT-PCR). The results showed higher frequency of RA in women than in men with elevate incidence in patients aged 40-59 years and 1-2 years RA disease duration of. The level of IL-17 was significantly higher in serum of RA patients compared with the control group (p < 0.0001). IL-17 level was significantly increased among the patients in RA stage 4 (p < 0.0001). IL-17 level was significantly increased in patients without treatment compared with treated patients. The expression of miRNA-146a was significantly higher in the patients' group than control group. In conclusion, IL-17 may play critical role in chronic inflammation and can be used as diagnostic biomarker for RA. miRNA-146a is overexpressed in RA patient relative to healthy individuals and it acts as a negative regulator for IL-17.
FIELD: cosmetology. SUBSTANCE: the suggested composition deals with washing and treating hair and/or head skin. It contains in an aqueous medium: at least, one active substance chosen out of corticoids and retinoids, at least, one anionic surface-active substance (SAS), at least, one amphoteric SAS and, at least, one impregnating agent. The suggested composition enables to improve penetration of active substance and achieve good cosmetic properties. EFFECT: more simplified technique. 30 cl, 14 ex
FIELD: food industry. SUBSTANCE: additive, as source of macro- and trace minerals and biologically active substances, contains cryogenically dried powders of vegetable and/or berry and/or fruit and/or melon vegetable and/or bean and/or green vegetable and/or cereal and/or algae and/or egg shell and/or vegetable drug materials and/or crustacea, reptile, and mollusk shells. Additive van also contain bacteria, phages, immuno-histamine preparations, and binding agents. Additive in dosed form can be identified in human body and possesses prolonged effect in heavy metal withdrawal, elevated antiallergic effect, and raises body's immune condition. EFFECT: extended choice of biologically active food additives. 11 cl, 10 ex
PURPOSE:To provide a dextranase-containing composition for oral cavity application, containing dextranase in stable form and odorizable freely, by compounding a specific tasteless and odorless higher aliphatic alcohol to dextranase useful as an agent for preventing the formation of dental plaque. CONSTITUTION:A composition for oral cavity application and containing dextranase is compounded with a 18-28C higher aliphatic alcohol as a stabilizer. The higher aliphatic alcohol is effective to stabilize dextranase. There is no limitation in the kind of perfume because the alcohol is tasteless and odorless in itself. The higher aliphatic alcohol is especially preferably jojoba alcohol. The amount of the alcohol is preferably 0.01-10wt%.
<P>PROBLEM TO BE SOLVED: To provide a linear DNA construct especially useful for human genetic therapy, to provide a method for producing a protein used for the construct, to provide a method for altering the expression of a gene existing in primary or secondary cell, to provide a method for producing a transfected primary or secondary cell or the clone cell strain of the transfected secondary cell, and to provide the clone cell strain of the transfected secondary cell.  <P>SOLUTION: This linear DNA construct alters the expression of a targeting cell in a cell, when a DNA construct containing (a) a targeting sequence homologous to a targeting site and (b) an exogenous regulatory sequence is homologously recombined at a targeting site in chromosomal DNA of a cell, wherein each terminal of the DNA construct is a single strand projection produced with an exonuclease. The method for producing a protein with the construct. The method for altering the expression of a gene existing in the primary or secondary cell. The method for producing the transfected primary or secondary cell or the clone cell strain of the transfected secondary cell. And the clone cell strain of the transfected secondary cell.  <P>COPYRIGHT: (C)2003,JPO
INTRODUCTION: Long-term endurance exercise is suspect to elevate the risk of atrial fibrillation (AF), but little is known about cardiovascular outcome and disease progression in this subgroup of AF patients. We investigated whether previous exercise level determines cardiovascular outcome.
METHODS: In this post hoc analysis of the RACE 4 randomized trial, we analyzed all patients with a completed questionnaire on sports participation. Three subgroups were made based on lifetime sports hours up to randomization and previous compliance to the international physical activity guidelines. High lifetime hours of high dynamic activity patients were defined as more than 150 min·wk -1 of high-intensity physical exercise. The primary endpoint was a composite of cardiovascular death and hospital admissions.
RESULTS: A total of 879 patients were analyzed, divided in 203 high lifetime hours of high dynamic activity, 192 high lifetime hours of activity, and 484 low lifetime hours of activity patients. Over a mean follow-up of 36 months (±14), the primary endpoint occurred in 61 out of 203 (30%) high lifetime hours of high dynamic activity, 53 out of 192 (27%) high lifetime hours of activity, and 135 out of 484 (28%) low lifetime hours of activity patients ( P = 0.74). During follow-up, 42 high lifetime hours of high dynamic activity (35%), 43 high lifetime hours of activity (32%), and 104 low lifetime hours of activity patients (34%) with paroxysmal AF received electrical or chemical cardioversion or atrial ablation ( P = 0.90).
CONCLUSIONS: In patients included in the RACE 4, there seems to be no relation between previous activity levels and cardiovascular outcome and the need for electrical or chemical cardioversion or atrial ablation. Cardiovascular outcome was driven by AF-related arrhythmic events.
This is a completely register-based observational cohort study. The study population is defined from the Swedish Quality Registry for Pain Rehabilitation (SQRP), which routinely aggregates data from specialist IDT pain management clinics across Sweden. SQRP contains information on the exposure/intervention: whether a patient that visited a SQRP-affiliated clinic was allocated to an IDT program (test) or not (control); t0 defined as the day of the IDT assessment. Microdata from SQRP is linked to other Swedish registers via the unique personal identification number held by all Swedish residents. Outcome data is obtained from the Swedish Social Insurance Agency. Registers managed by the National Board of Health and Welfare include data on dispensed prescription pharmaceuticals and specialist health care.

Markov multistate survival-based methods will be used to compare the sickness absence between groups. Specifically, length of stay per sickness absence state (no sickness absence, sick leave, and disability pension) will be compared over five years from t0. Both crude and adjusted estimates will be presented. Adjustment will be made based on our hypothesis about causal relationships and include: history of sickness absence, sociodemographics (age, sex, sociodemographic status), patient disability (emotional distress, everyday interference, and confidence in future improvement), and governmental policy (IDT assessment year and geographical region of IDT clinic).
Disclosed is a method for the treatment of a neurodegenerative disorder by isolating a plurality of monocytic cells and introducing a vector containing a gene that expresses a protease capable of degrading amyloid peptide into the isolated monocytic cells. The modified cells are then administered to the patient. Preferably the introduced gene is selected from the group consisting of neprilysin, insulin degrading enzyme and endothelin converting enzyme. The protease capable of degrading amyloid peptide is secreted from the monocytic cells into the extracellular space thereof. According to one variant, the gene that expresses a protease capable of degrading amyloid peptide is the NEP gene with a deletion in the membrane binding domain and/or an appended signal peptide to drive secretion of the modified gene product. This invention contemplates the use of heterologous and autologos (the monocytic cells are obtained from the patient) transplants.
Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
Methods and products for upregulating cystic fibrosis transmembrane conductance regulators are provided, including methods and products for the treatment of P. aeruginosa infection. The products include polysaccharides that interact with the cystic fibrosis transmembrane conductance regulator (CFTR). The polysaccharide compositions of the invention may be administered to a subject in order to enhance the uptake of P. aeruginosa into the epithelial cells of the subject. The invention also encompasses compositions comprising a lipopolysaccharide-binding region of a CFTR linked to an anti-Pseudomonal drug and methods of use of such compositions. Compositions and methods for gene therapy are also disclosed. The compositions include polysaccharides that bind to CFTR coupled to a gene delivery vehicle.
Patients undergoing standard of care surgical evacuation of cSDH. will have subdural ECoG monitoring electrode placed crossing frontal and temporal lobes for 1-5 days of post operative monitoring. All subjects will undergo long term followup testing.
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA.

Overall, MDS/AML has been reported in 0.4% (3 out of 788) of solid tumor patients treated with TALZENNA as a single agent in clinical studies. In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide [see Adverse Reactions (6.1)]. The durations of TALZENNA treatment in these five patients prior to developing MDS/AML were 0.3, 1, 2, 3, and 5 years, respectively. Most of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy.

Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA.
A nimustine slow release injection for treating solid cancer comprises slow release finding and nimustine, or the combination of nimustine and relative booster (pidorubicin, osaliplatinum, adriablastina, amethopterin or the like). The viscidity of slow-release injection is 10-650cp (20-30Deg. C). The anti-cancer effective component can be made into slow release plant agent. The slow release finding substantially comprises macromolecule polymer with biological soluble degradable and absorb property, which can slow release the anti-cancer effective component to cancer part in the degradation process, significantly reduce general reaction and hold effective drug density on cancer. The anti-cancer compound can be arranged part of cancer to reduce the general toxicity reaction, selectively improve the drug density locally, and strengthen the effect of non-surgery treatments as chemotherapy, and radiation therapy or the like. The solid cancer comprises glioma, lung carcinoma, intestinal cancer, breast cancer or the like.
A process for producing a ceramic body suitable for surgical implantation that has high strength and toughness and good compatibility with bone material. A porous material is provided by semi-sintering a ceramic compact. The pores in the surface of the porous material are filled with a first powder of either tricalcium phosphate or apatite or both, or with a material of the fine powder and a powder of a material substantially the same as the material of the ceramic compact. The porous material is then fired at the sintering temperature of the ceramic compact. Following sintering, the surface of the porous material is coated with a fine apatite powder or a finally pulverized mixture of apatite and a calcium phosphate base frit. The resulting assembly is then fired at a temperature up to about 1,350° C.
BACKGROUND: Overactive bladder (OAB) is a common condition in middle-aged and older women. It has been reported to be potentially linked to cognitive decline, particularly in older adults. This study investigated the association between OAB symptoms and cognitive impairment in middle-aged women.
MATERIALS AND METHODS: This cross-sectional study had a sample of 1652 women (mean age 49.3 ± 2.8 years) who were not taking medication for either urinary tract infection or OAB. OAB symptoms and cognitive function were evaluated by self-administered questionnaires: the Overactive Bladder Symptom Score and the Alzheimer's disease 8. Logistic regression models estimated prevalence ratios (PRs) with 95 % confidence intervals (CI) for cognitive impairment according to the presence/absence of OAB. Mediation analyses assessed the impact of poor sleep quality on this association.
RESULTS: Cognitive impairment was more prevalent in women with OAB than in those without OAB (multivariable-adjusted PR: 1.88 [95 % CI: 1.52-2.24]). Women experiencing nocturia (≥twice a night), urinary urgency at least once a week, and urgency urinary incontinence at least once a week had multivariable-adjusted PRs (95 % CI) for cognitive impairment of 2.08 (1.50-2.65), 2.12 (1.66-2.58), and 1.75 (1.17-2.34), respectively. Poor sleep quality mediated 10.81 % [95 % CI: 4.55-19.44 %] of the relationship between OAB and cognitive impairment.
CONCLUSIONS: Among middle-aged women not taking OAB medications, OAB symptoms were associated with cognitive impairment, partly because of poor sleep quality. Further research is needed to determine whether early screening of patients with OAB can help identify those susceptible to cognitive impairment associated with OAB medication and if preventive measures should be targeted at this group.
Breeding high yielding water-deficit tolerant rice is considered a primary goal for achieving the objectives of the sustainable development goals, 2030. However, evaluating the performance of the pre-breeding-promising parental-lines for water deficit tolerance prior to their incorporation in the breeding program is crucial for the success of the breeding programs. The aim of the current investigation is to assess the performance of a set of pre-breeding lines compared with their parents. To achieve this goal a set of 7 pre-breeding rice lines along with their parents (5 genotypes) were field evaluated under well-irrigated and water-stress conditions. Water stress was applied by flush irrigation every 12 days without keeping standing water after irrigation. Based on the field evaluation results, a pre-breeding line was selected to conduct physiological and expression analysis of drought related genes at the green house. Furthermore, a greenhouse trial was conducted in pots, where the genotypes were grown under well and stress irrigation conditions at seedling stage for physiological analysis and expression profiling of the genotypes. Results indicated that the pre-breeding lines which were high yielding under water shortage stress showed low drought susceptibility index. Those lines exhibited high proline, SOD, TSS content along with low levels of MDA content in their leaves. Moreover, the genotypes grain yield positively correlated with proline, SOD, TSS content in their leaves. The SSR markers RM22, RM525, RM324 and RM3805 were able to discriminate the tolerant parents from the sensitive one. Expression levels of the tested drought responsive genes revealed the upregulation of OsLEA3, OsAPX2, OsNAC1, OSDREB2A, OsDREB1C, OsZIP23, OsP5CS, OsAHL1 and OsCATA genes in response to water deficit stress as compared to their expression under normal irrigated condition. Taken together among the tested pre-breeding lines the RBL112 pre-breeding line is high yielding under water-deficit and could be used as donor for high yielding genes in the breeding for water deficit resistance. This investigation withdraws attention to evaluate the promising pre-breeding lines before their incorporation in the water deficit stress breeding program.
PURPOSE:To obtain an ultraviolet absorbing agent composed of an extract of bark of Lindera umbellata Thunb belonging to the family Lauraceae, capable of absorbing ultraviolet A and ultraviolet B, having high safety, excellent in ultraviolet protecting function and useful as a cosmetic. CONSTITUTION:This ultraviolet absorption agent is composed of an extract of bark of Lindera umbellata Thunb belonging to the family Lauraceae. Further, an ultraviolet-protecting cosmetic is produced by compounding 0.01-10wt.% of the absorbing agent based on the total cosmetic, especially preferably 0.1-1wt.%. The extract of bark of Lindera umbellata Thunb belonging to the family Lauraceae is obtained by immersing bark of Lindera umbellata Thunb or the pretreated bark preferably in 1-100 times of a polar solvent such as water, methanol, acetone or chloroform for several hours under heating or for several days at the room temperature. The obtained extract is used as it is or after fractionation by column chromatography, etc. Further, the extract may be formulated into a cosmetic e.g. in a form of a lotion, a cream, etc. These cosmetics are useful for protecting the skin or the hair from ultraviolet.
Acute carotid stenting (ACS) approach constitutes BMM+IAT with acute carotid stenting (ACS) of the extracranial proximal carotid artery, spanning the cervical internal carotid artery (ICA), ICA origin, and the distal common carotid artery (CCA, across the bifurcation) as in the example of left (L) carotid stenting figure below (MT+CAS). Within the stenting arm, there will be 2 different subgroups based on the antiplatelet treatment protocol per the site standard of care (oral antiplatelet or IV antiplatelet medication (e.g., Cangrelor or others).
This treatment arm (also called the "simple treatment" arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis.
Carcinogenesis: Long-term studies in animals to evaluate carcinogenic potential have not been conducted with polymyxin B sulfate or trimethoprim.

Mutagenesis: Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. In studies at two laboratories no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels after oral administration; at concentrations approximately 1,000 times human plasma levels after oral administration in these same cells, a low level of chromosomal damage was induced at one of the laboratories. Studies to evaluate mutagenic potential have not been conducted with polymyxin B sulfate.

Impairment of Fertility: Polymyxin B sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.
Generalized Pustular Psoriasis (GPP) is a dermatological autoinflammatory disease that rarely occurs in children and is associated with complex genetic factors. GPP pathogenesis has been associated with mutations in IL36RN gene, which encodes an interleukin-36 receptor antagonist. GPP usually occurs without a history of psoriasis in the patients or their family members. This case report describes the clinical course of a 3-year-old toddler with GPP. The diagnosis of GPP was confirmed through a comprehensive series of examinations, and genetic testing revealed an IL36RN mutation, providing further insight into the genetic basis of the condition. This case highlights the importance of a genetic perspective for diagnosing GPP, particularly in children.